SNDX Stock: Price, Earnings History and SEC Filings
Syndax Pharmaceuticals, Inc. (SNDX) last traded at $13.65, down 3.53% on the latest session and down 27.4% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.55 against an analyst estimate of $-0.45, a miss of 22.2%.
$13.65 -3.53%
1 month-27.39%
52-week high$25.59
52-week low$12.80
Volume2.54M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
SNDX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | $-0.55 | $-0.45 | -22.22% |
| Mar 2026 | Apr 30, 2026 | $-0.48 | $-0.59 | +18.64% |
| Dec 2025 | Feb 26, 2026 | $-0.78 | $-0.64 | -21.88% |
| Sep 2025 | Nov 3, 2025 | $-0.70 | $-0.74 | +5.41% |
SNDX beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for SNDX
SEC filing data is not available right now. You can search for SNDX on SEC EDGAR.
SNDX news
- Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan DiseasesOct 30, 2026 · finance.yahoo.com
- Syndax Announces Participation in November Investor ConferencesOct 30, 2026 · finance.yahoo.com
- Earnings Preview: Niagen Bioscience (NAGE) Q3 Earnings Expected to DeclineOct 28, 2026 · finance.yahoo.com
- Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseOct 26, 2026 · finance.yahoo.com
- Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026Oct 26, 2026 · finance.yahoo.com
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc. (SNDX) is a US-listed public company on Nasdaq.